Codexis (CDXS) to Post Earnings on Tuesday

Codexis (NASDAQ:CDXS) will likely be issuing its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.17) per share and revenue of $13.8240 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. Codexis had a negative return on equity of 68.09% and a negative net margin of 40.97%.The company had revenue of $15.25 million during the quarter, compared to analysts’ expectations of $14.53 million. On average, analysts expect Codexis to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Codexis Price Performance

Shares of CDXS traded up $0.02 during trading hours on Tuesday, hitting $1.47. The stock had a trading volume of 221,164 shares, compared to its average volume of 1,606,534. The stock has a market capitalization of $133.53 million, a price-to-earnings ratio of -3.97 and a beta of 2.54. The company has a debt-to-equity ratio of 0.94, a current ratio of 5.36 and a quick ratio of 5.23. The company’s fifty day moving average is $2.30 and its two-hundred day moving average is $1.99. Codexis has a 52 week low of $0.96 and a 52 week high of $3.87.

Institutional Investors Weigh In On Codexis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its position in shares of Codexis by 41.8% during the 4th quarter. Invesco Ltd. now owns 174,590 shares of the biotechnology company’s stock worth $285,000 after buying an additional 51,454 shares during the period. XTX Topco Ltd raised its position in shares of Codexis by 330.9% in the 4th quarter. XTX Topco Ltd now owns 74,558 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 57,254 shares during the period. Quadrature Capital Ltd boosted its stake in Codexis by 102.2% during the 4th quarter. Quadrature Capital Ltd now owns 54,435 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 27,509 shares during the last quarter. Bridgeway Capital Management LLC boosted its stake in Codexis by 49.6% during the 4th quarter. Bridgeway Capital Management LLC now owns 150,908 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Guggenheim Capital LLC acquired a new position in Codexis during the fourth quarter valued at approximately $45,000. Institutional investors own 78.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on CDXS shares. Weiss Ratings raised Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Codexis in a report on Wednesday, June 17th. Finally, Wall Street Zen downgraded shares of Codexis from a “buy” rating to a “hold” rating in a research note on Sunday, May 3rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $5.00.

About Codexis

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.